Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Pedram Gerami MD

Pedram Gerami MD

IDP Endowed Professor of Skin Cancer Research; Director, Skin Cancer Institute of Northwestern Medicine; Director, Melanoma Program, Skin Cancer Institute; Director, Melanoma Clinic, Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Dr. Gerami is the director of the Skin Cancer Institute of Northwestern Medicine (SCIN-Med) and the director of the Melanoma Program in the Skin Cancer Institute and the Melanoma clinic in the department of Dermatology. His clinical and research interests are primarily focused on melanoma skin cancer, atypical nevi and borderline melanocytic tumors such as Spitz tumors which maybe difficult to classify.

As a dermatologist, dermatopathologist and researcher focused in the care of patients with melanoma and atypical nevi, he has a unique perspective on the behavior of melanocytic neoplasms. His interests include how to utilize clinical, histologic and molecular diagnostic methods to optimize diagnostic accuracy and best predict the behavior of melanocytic neoplasms as well as developing methods for diagnosis of melanoma skin cancer at its earliest and most curable stage.

In clinic, he primarily cares for patients with melanoma or atypical nevi. He is recognized internationally for his expertise in the clinical and histologic diagnosis of melanoma. His expertise in the pathologic diagnosis of melanoma draws more than 1500 second opinion cases both from within and outside of the United States per year. As a researcher he is focused on developing newer molecular based methods to help distinguish melanoma from nevi and predict the behavior of melanoma and developing methods for diagnosis of melanoma at the earliest possible stage.